Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer-Reference-Cited by-同舟云学术

Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer

Published:2020-11 Issue:11 Volume:80 Page:1115-1122
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Tesch Hans¹,Müller Volkmar²,Wöckel Achim³,Ettl Johannes⁴,Belleville Erik⁵,Schütz Florian⁶,Hartkopf Andreas⁷,Thill Marc⁸,Huober Jens⁹,Fasching Peter A.¹⁰,Kolberg Hans-Christian¹¹,Schulmeyer Carla E.¹⁰,Welslau Manfred¹²,Overkamp Friedrich¹³,Fehm Tanja N.¹⁴,Lux Michael P.¹⁵,Schneeweiss Andreas¹⁶,Lüftner Diana¹⁷,Janni Wolfgang⁹

Affiliation:

1. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany

2. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

3. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

4. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

5. ClinSol GmbH & Co. KG, Würzburg, Germany

6. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany

7. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

8. Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany

9. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

10. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

11. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

12. Onkologie Aschaffenburg, Aschaffenburg, Germany

13. OncoConsult Overkamp, Berlin, Germany

14. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

15. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany

16. National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

17. Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany

Abstract

AbstractSubstances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynaecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1270-7481.pdf

Reference45 articles.

1. Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer;F Schutz;Geburtshilfe Frauenheilkd,2019

2. Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer;M Welslau;Geburtshilfe Frauenheilkd,2019

3. Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer;A D Hartkopf;Geburtshilfe Frauenheilkd,2019

4. Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice;W Janni;Geburtshilfe Frauenheilkd,2019

5. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry;M P Lux;Cancers (Basel),2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer;npj Breast Cancer;2024-07-13

2. Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebszentrums;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-05-23

3. Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-06

4. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer;Geburtshilfe und Frauenheilkunde;2023-03

5. Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-02-28